An application made for this job — a tailored resume and cover letter that speak straight to the posting.
Celcuity is a commercial biotechnology company pursuing development of targeted therapies for solid tumor indications.
This role leads commercial supply planning, drives monthly S&OP, translates demand forecasts into supply plans, and manages inventory to target safety stock levels.
This role will lead commercial supply planning at Celcuity, which includes the management of monthly S&OP meetings, translation of demand forecasts into supply plans, ensuring supply plans are in alignment with budget, management of inventory to desired safety stock levels, issuance of purchase orders and production forecasts to suppliers, scenario planning to enable supply decisions, and support of business process improvements.
Celcuity is an Equal-Opportunity Employer.
Celcuity is committed to fair and equitable compensation practices, and we strive to provide employees with total compensation packages that are competitive. For this role, the anticipated base pay range is $150,000 - $190,000 DOE. The exact base pay offered for this role will depend on various factors, including but not limited to the candidate’s geography, qualifications, skills, and experience.
The successful candidate will be eligible for an annual performance incentive bonus and a new hire equity package. Celcuity also offers various benefits offerings, including, but not limited to, medical, dental, vision insurance, 401(k) match, PTO, and paid holidays.
Celcuity is a commercial biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. REVTORPYK is approved to treat adults with HR+/HER2- advanced breast cancer that progressed on prior endocrine therapy in the metastatic setting.
The Phase 3 VIKTORIA-2 trial is evaluating gedatolisib in combination with palbociclib and either fulvestrant or letrozole for the first-line treatment of HR+/HER2- locally advanced or metastatic breast cancer. A Phase 1/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing.